O'Malley, David M <br/><br/>
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.  [electronic resource] 

 -  Gynecologic oncology  05 2020 
 - 379-385 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1095-6859 
<br/><br/><label>Standard No.: </label>10.1016/j.ygyno.2020.01.037  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Bevacizumab--administration & dosage<br/>Carcinoma, Ovarian Epithelial--drug therapy<br/>Drug Resistance, Neoplasm<br/>Female<br/>Folate Receptor 1--immunology<br/>Humans<br/>Immunoconjugates--administration & dosage<br/>Maytansine--administration & dosage<br/>Middle Aged<br/>Organoplatinum Compounds--pharmacology<br/>Ovarian Neoplasms--drug therapy<br/>Progression-Free Survival